Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention ...
read more
The potential growth difference for the Krabbe disease treatment market between 2021 and 2026 is $438.03M. The market is driven by special drug designation.
read more
FDA Approves Camzyos™ (mavacamten) forTreatment of HCM
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive ...
read more
Highland Therapeutics Inc., a privately held pharmaceutical company that through its wholly owned subsidiary, Ironshore Pharmaceuticals Inc., is focused on the commercialization of JORNAY PM® (methylphenidate HCl) extended-release capsules (CII) for patients with ADHD, announced the appointment of Stephanie C. Read as President/Chief Executive ...
read more
The global pharmaceutical processing and packaging equipment market is expected to grow at a CAGR of 4.5% from 2021 to 2028 to reach $25.2 billion by 2028, according to a new report.
read more
The global probiotics market size is expected to reach $111.21B by 2030 and is expected to expand at a CAGR of 7.5% from 2021 to 2030. The increasing prominence of preventive healthcare is among the major factors propelling the demand for probiotics across the globe.
read more
The global high maltose syrups market is predicted to expand at a CAGR of 4.4% and climb to a market valuation of US$ 1.88 Bn by the end of 2032.
read more
PharmaCyte Biotech, a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity.
read more
Breckenridge Pharmaceutical, Inc. announced the launch of Lacosamide Tablets, USP (generic version of Vimpat®). The product was developed and will be manufactured by MSN Laboratories Private Limited and marketed by Breckenridge in the US.
read more
The U.S. clinical trial supplies market size was estimated at $5,661.62Min 2021, $6,090.81M in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.66% to reach $8,818.82 million by 2027, according to a report by Research & Markets.
read more
Le-Vel, a nutrition and skincare company, announced the appointment of Carmen Wasserman to the position of Chief Legal Officer, effective immediately.
read more
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. difficile infection (CDI).
read more
The Latin America pharmaceutical contract manufacturing organization market is expected to register a CAGR of 3.3% during the forecast period 2020 - 2025. Being one of the North American Free Trade Agreement members, Mexico has access to the best established and emerging pharmaceutical markets in North and Latin America.
read more
Biohaven has secured additional commercial insurance coverage for Nurtec ODT starting in April 2022 that expands the total number of commercial lives covered to 96 percent or approximately 255 million people via all channels.
read more
Catalent announced that it has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms.
read more